Trial Profile
Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms SUSTAIN; SUSTAIN JAPAN
- Sponsors Novo Nordisk
- 25 Sep 2020 Results (n=9680) of analysis from twelve clinical studies: SUSTAIN 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 and two Japanese SUSTAIN trials assessing risk predictors for Gastrointestinal adverse events with once weekly subcutaneous Semaglutide identifying high-risk patients presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 01 Aug 2018 Results published in the Diabetes Therapy.
- 15 Dec 2017 According to a Novo Nordisk media release, the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) has adopted a positive opinion, recommending marketing authorisation for Ozempic (semaglutide) for the treatment of adults with type 2 diabetes mellitus.